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Therapeutic Intervention in Acute 
Ischemic Stroke: a Paradigm Shift
Antonis S. Manolis, MD,1 Theodora A. Manolis, MS2
A B S T R A C T
In parallel to the situation of acute myocardial infarction, timely restoration of blood 
flow (reperfusion) using thrombolytic therapy or percutaneous intervention is the key 
and most effective strategy for salvaging ischemic brain tissue in acute ischemic stroke 
(AIS). There is a narrow therapeutic window (up to 3-4.5 hours) during which this can 
be accomplished, since the benefit of reperfusion continually decreases over time. 
During the acute phase of cerebral ischemia, a rapid determination and triaging of pa-
tients who are eligible for reperfusion is key to the success of such a salvaging strategy. 
Reperfusion in AIS can be effected via thrombolysis, already an FDA approved strat-
egy, while newly emerging endovascular interventional techniques have been added to 
our therapeutic armamentarium.
I N T R O D U C T I O N
Each year, ~795 000 people in the USA and >1 million in Europe experience a new 
or recurrent stroke.1 According to data from the Northern Manhattan study (2005), 
the age-adjusted incidence of first ischemic stroke per 100 000 was 88 in whites, 191 
in blacks, and 149 in Hispanics. On average, every 40 seconds, someone in the USA 
has a stroke, and every 4 minutes, someone dies of a stroke.1 Stroke ranks third among 
all causes of death after heart disease and cancer, and is a leading cause of serious, 
long-term disability. However, on an optimistic note, from 1996 to 2006, the annual 
stroke death rate decreased 33.5%, and the actual number of stroke deaths declined 
18.4%. Although stroke is often considered a disease of the elderly, one third of strokes 
develop in individuals younger than 65 years of age. Risk of stroke increases with age, 
especially in patients older than 65 years, in whom 75% of all strokes are observed. One 
in 6 individuals will have a stroke at some point in their lifetime; approximately 85% 
of people afflicted by stroke will have risk factors which, if identified, are modifiable 
and preventable (Table 1).
C L A S S I F I C A T I O N  A N D  P A T H O P H Y S I O L O G Y
Strokes are classified as ischemic or hemorrhagic.2,3 Acute ischemic strokes (AIS) 
caused by acute cerebral vessel occlusion are more common (80-87%)1,2 than hemor-
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rhagic and they refer to thrombosis or embolism. They are 
classified into large (~20%) artery infarctions, small vessel 
(25%) or lacunar infarctions and cardioembolic (20%) infarc-
tions. Ischemic strokes are commonly caused by atheroscle-
rotic disease of extracranial or intracranial vessels perfusing 
the brain. Cardioembolic AIS are most frequently caused by 
atrial fibrillation. Approximately 30% of ischemic strokes 
are termed cryptogenic, for which the exact cause of stroke 
remains unknown.
Ischemic stroke develops from acute vascular occlusion 
which produces regions of ischemia in the affected brain tissue. 
Local cerebral blood flow is consisted of any residual flow in 
the major artery and the collateral supply, if any. Regions of 
the brain with cerebral blood flow <10 ml/100 g of tissue/min 
are referred to as the core, and these brain cells are supposed 
to die within minutes of the onset of stroke (permanently 
damaged/necrotic area). Zones of diminished or marginal 
perfusion (cerebral blood flow <25 ml/100 g of tissue/min) are 
designated as the (hypoperfused) ischemic penumbra. Tissue 
in the penumbra may remain viable for several hours because 
of marginal brain tissue perfusion; the ischemic penumbra is 
present in ≥80% of patients in the first 3 hours, but diminishes 
rapidly thereafter and it is the target to be salvaged by reperfu-
sion and recanalization. Thus, “time is brain” (analogous to 
“time is muscle” in acute myocardial infarction) and a race 
against time should be the top priority of any health care 
system providing services to patients with AIS. Hemorrhagic 
transformation (conversion of a necrotic infarction into an area 
of hemorrhage) is estimated to occur in 5% of uncomplicated 
ischemic strokes, in the absence of thrombolytics. It occurs 
within 2-14 days post ictus, usually within the first week. It is 
more commonly seen with cardioembolic strokes, larger infarct 
size and following thrombolysis.
M O R T A L I T Y  A N D  R I S K  F A C T O R S
Strokes incur significant morbidity and mortality and im-
pose an insurmountable emotional and economical burden 1 
to patients, families and society. The death rate (per 100 000 
population) is estimated at 32.3 for the USA, 32.7 for the Uk, 
58.4 for Greece, 27.7 for France, 31.9 for Italy and 39.2 for 
Spain (years 2006-2007).1 In a study of persons ≥65 years of 
age, in 4 USA communities, the 1-month case fatality rate was 
12.6% for all strokes, 8.1% for ischemic strokes, and 44.6% for 
hemorrhagic strokes. In a report released by the Centers for 
Disease Control (CDC), 30-day stroke mortality rate varied 
by age: 9% in patients 65 to 74 years of age, 13.1% in those 
74 to 84 years of age, and 23% in those ≥85 years of age. The 
cost estimate of stroke for 2010 in the USA culminates to 
$73.7 billion.1 Among the modifiable risk factors for stroke, 
prominent place is held by coronary heart disease, hyperten-
sion, smoking, diabetes mellitus, atrial fibrillation, sickle cell 
disease, dyslipidemia, asymptomatic or symptomatic (transient 
ischemic attacks) carotid stenosis, obesity, physical inactivity, 
and post-menopausal hormone therapy (Table 1). Although 
primary prevention of stroke concentrating on these modifi-
able risk factors would be an ideal approach, it still lacks imple-
mentation and efficacy, and thus more effective management 
strategies are needed to cope with this devastating disease. 
R E P E R F U S I O N
As timely restoration of blood flow (reperfusion) using 
thrombolytic therapy or percutaneous intervention is the key 
and most effective strategy for salvaging ischemic myocardial 
tissue in acute myocardial infarction, the same principle applies 
to AIS. There is a narrow therapeutic window during which 
this can be accomplished, since the benefit of reperfusion 
TABLE 1. Modifiable Risk Factors for Ischemic Stroke1 
Factor Relative Risk
Coronary heart disease 1.6
Hypertension 1.0-4.0 
(reverse age-dependent)*
Smoking 1.8
Diabetes 1.8-6.0 
Carotid stenosis 2.0
Atrial fibrillation /flutter 2.6-4.5 
Sickle cell disease 200-400
Dyslipidemia 1.5-2.5
Obesity 1.7-2.4
Physical inactivity 2.7
Early menopause/Postmenopausal 
hormone therapy
1.4-2.0
Elevated plasma homocysteine 2.2
Depression 4.0
Pregnancy/Post-pregnancy period 2.4
Structural heart disease: myocardial 
infarction, LV aneurysm, dilated 
cardiomyoapthy, endocarditis, 
valvular disease (e.g. mitral stenosis), 
intracardiac communications  
(e.g. ASD or PFO)
NA
Illicit drug use NA
ASD = atrial septal defect; LV = left ventricular; PFO = patent 
foramen ovale; NA = not available
*Although clearly important even in the elderly, the impact of 
hypertension, as a risk factor for stroke, may decrease with increasing 
age; the relative risk (odds ratio) is 4 at age 50, decreasing to 1 by age 90
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continually decreases over time. During the acute phase of 
ischemia, be it myocardial or cerebral, a rapid determination 
and triaging of patients who are eligible for reperfusion is 
key to the success of such a salvaging strategy. Reperfusion 
in AIS can be effected via thrombolysis, already a Food and 
Drug Administration (FDA) approved strategy, while newly 
emerging endovascular interventional techniques are added 
to our therapeutic armamentarium.4 
T H R O M B O LY S I S
The initial evidence that thrombolysis was effective in AIS 
was provided in 1995 with the publication of the National 
Institute of Neurological Disorders and Stroke (NINDS) trial 
showing thrombolysis to be beneficial in selected patients, if 
administered within 3 hours from onset.5 This trial initially 
received considerable scepticism, mostly due to the fact that it 
was a single randomized trial of 624 patients that proposed a 
significant change in the management of acute ischemic strokes 
with adoption of a potentially dangerous mode of therapy. 
There followed 3 more studies (ECASS I & II, ATLANTIS) 
which were negative,6-8 but pooled data from all these 4 trials 
(NINDS, ECASS I, ECASS II, ATLANTIS),9 which included 
2775 patients treated up to 6 hours after symptom onset, were 
positive, supporting the results of the NINDS trial and demon-
strating that thrombolysis within 3 hours (and possibly up to 4.5 
hours) of symptom onset is associated with a greater chance of 
a favorable outcome at 3 months. Nevertheless, the paradigm 
shift in the management of acute ischemic stroke actually 
started with the ECASS III study,10,11 the second positive (after 
NINDS) randomized trial, which was published in September 
2008, and confirmed the effectiveness of thrombolysis with use 
of alteplase in treating acute ischemic stroke (Table 2). This 
was a study of 821 patients, randomized to receive alteplase or 
placebo, between 3 and 4.5 hours after the onset of an acute 
stroke. Conducted in Europe, the trial had a median time to 
administration of rt-PA (alteplase) of 4 hours. A total of 52.4% 
TABLE 2. Studies of Thrombolysis in Acute Ischemic Stroke
Study
No. of  
Patients
Mode of 
Therapy*
Timing of 
Therapy
Favorable 
Outcome 
Intracerebral  
Hemorrhage Mortality
NINDS5 624 IV <3 h Yes (32-55% ) 
(OR 1.7)
Higher  
(10.9% vs 3.5%)
Similar  
(17% vs 21%)
ECASS I6 620 IV <6 h No (14-15%) 
(OR 1.3)
Similar  
(42.8% vs 36.8%)
Similar  
(22.4% vs 15.8%) 
ECASS II7 800 IV <6 h No (3.7%)  
(OR 1.2)
Similar  
(48.4% vs 40.2%)
Similar  
(10.5% vs 10.7%)
ATLANTIS8 613 IV 3-5 h No (2%) Higher (2.6-11.3% vs 
0.3-4.2%) 
Similar  
(11% vs 6.9%)
STARS16 ** 389 IV <3 h Yes 10.5% 13%
SITS-MOST17 ** 6483 IV <3 h Yes (15%) 7.3% 11.3% 
ECASS III10 821 IV <3-4.5 h Yes (52.4% vs 45.2%) Higher  
(27% vs 17.6%)
Similar  
(7.7% vs 8.4%)
SITS-ISTR18,19 664/11865 IV 3-4.5 h vs <3 h No (58% vs 56.3%) Similar  
(14% vs 16.4%)
Similar  
(12.7% vs 12.2%)
CASES14 1112 IV 3-5 h vs <3 h No (39.4% vs 36.5%) Similar  
(7.8% vs 3.8%) 
Similar  
(28.4% vs 21.4%) 
EPITHET28 101 IV 3-6 h Yes (30%) Higher (7.7% vs 0%) Similar (25% vs 14%) 
DEFUSE29 74 IV 3-6 h Yes (42%) (OR 5.4) 9.5% 4%
PROACT II22 180 IA † <6 h Yes (40% vs 25%)  
(OR 2.1) 
Higher (10% vs 2%) Similar  
(25% vs 27%)
IMS24 80 IV+IA <3 h Yes (30% vs 18%)  
(OR > 2.0) 
Similar  
(6.3% vs 6.6%)
Similar  
(16% vs 24%) 
EMS27 25 IV+IA vs IA <3 h No (24% vs 24%) Higher  
(35.3% vs 11.1%)
Increased  
(29% vs 5.5%)
h = hours; IA = intraarterial; IV = intravenous; OR = odds ratio, *rt-PA, unless otherwise specified, **prospective observational study, 
†recombinant pro-urokinase plus IV heparin vs IV heparin / recanalization rate 66% vs 18%
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of patients given alteplase compared with 45.2% receiving 
placebo had a ‘favorable outcome’ (defined as little or no dis-
ability) (p=0.04). The incidence of intracranial hemorrhage 
was significantly higher in the alteplase group compared with 
the control group, however, mortality did not differ between 
the two groups (7.7% mortality in alteplase versus 8.4% in 
control; p=0.68). This trial was the second randomized trial 
after the NINDS trial to show benefit from the administration 
of a thrombolytic agent in acute ischemic stroke, and extended 
the time window of thrombolytic therapy up to 4.5 hours after 
the onset of the symptoms of stroke, and this was endorsed 
by the AHA and the American Stroke Association guidelines 
in May 2009.12,13 
A recent prospective multicenter study from a Canadian 
registry (CASES)14 comprising 1112 patients indicated that 
patients with acute ischemic stroke had a trend for better out-
come if treated early with rt-PA within the 3-hour compared 
with the 3-4.5-hour treatment window, and cautioned that 
later time window treatment may result in greater adverse 
events.14 However, analysis of data from 66 MRI-selected 
patients receiving rt-PA 3-6 hours after symptom onset and 
comparing them with 108 patients presenting within 3 hours 
and with pooled data from the ATLANTIS, ECASS, and 
NINDS trials (1085 patients), indicated a favorable outcome 
in MRI-selected patients similar to those treated within 3 
hours and better that those of the pooled analysis.15 The rate 
of symptomatic intracerebral hemorrhage in MRI-selected 
patients (3%) was lower than in the pooled rt-PA group (8%) 
and comparable to the rate in 1081 patients of the pooled 
placebo group (2%). This study supports the expansion of the 
time window for rt-PA administration up to 6 hours in patients 
with brain tissue at risk as defined by MRI.
A list of major trials on use of thrombolysis, mostly with 
rt-PA, in AIS is furnished in Table 2.5-11,16-31 They provide 
consistent evidence of efficacy of thrombolysis in selected 
patients who present within 3 hours after AIS or even up to 5-6 
hours in certain patients. Intracranial hemorrhage constitutes 
a major hindrance to wider adoption and questions the safety 
of thrombolytic therapy (Table 2), albeit it only contributes 
to approximately 20% of deaths.10,20 Predictors of such a 
potentially catastrophic complication may include older age, 
hypertension, hyperglycemia and diabetes, baseline stroke 
severity (National Institutes of Health Stroke Scale-NIHSS 
score >20), baseline CT abnormalities, site and persistence of 
vascular occlusion, atrial fibrillation, concurrent heparin use 
and concomitant intake of antiplatelet agents.32-37 Measuring 
certain biomarkers, e.g. matrix metalloproteinase-9 indicating 
increased permeability of the blood brain barrier that leads to 
edema formation and hemorrhagic transformation, has been 
suggested as a means to predict this hemorrhagic complication 
of thrombolysis.33
The most common reason for ineligibility of administration 
of a thrombolytic in acute ischemic stroke is time delay; pa-
tients arrive too late and do not call emergency services in time. 
Education of the public, and targeted education of patients 
at high risk of stroke by their primary care physicians, could 
increase the number of stroke patients who arrive to emergency 
rooms within the time window for assessment and life-saving 
therapy. Family physicians should emphasize that patients pre-
senting with or calling in with symptoms and signs suggesting a 
stroke should be immediately directed to the closest emergency 
room. Acute stroke in the emergency room should be triaged 
and treated with the highest priority and urgency. Ideally, 
emergency room staff and stroke teams should be notified, if 
possible, by ambulance staff, prior to patient arrival. Prompt 
assessments should be made upon arrival and stroke patients 
should rapidly be taken to the CT scanner with the objective 
to determine whether the stroke is ischemic or hemorrhagic.38 
Alternatively, magnetic resonance imaging (MRI) may be used 
as the initial imaging modality for acute assessment.38 Most 
commonly an immediate unenhanced (noncontrast) head CT 
scan is obtained and still considered the gold standard in the 
management of AIS. Recent technology has ushered in more 
sophisticated perfusion-based imaging modalities, such as CT 
or MRI perfusion and CT angiography which provide a map of 
cerebral blood volume, cerebral blood flow, and mean transit 
time, able to identify the ischemic core and penumbra that can 
distinguish patient subgroups that will or will not benefit from 
reperfusion therapies and also guide the decision for applying 
additional interventional techniques.4,28,29,38 Of course, other 
diagnostic tests may be in order in AIS patients, such as carotid 
duplex scanning to screen for cervical vessel stenosis, cerebral 
angiography to accurately delineate the degree and site of 
vessel lesion and guide interventional therapy when such a 
decision is made, and finally transthoracic and transesophageal 
echocardiography to seek cardioembolic sources and define 
cardiac anatomy and function. 
The decision to thrombolyse patients should be a shared 
decision among patients, referring and treating physicians. The 
recombinant tissue palsminogen activator (rt-PA) is the only 
treatment for AIS approved by the US FDA, and it ideally 
should be administered within 3-4.5 hours of symptom onset. 
The rt-PA dose for AIS is 0.9 mg /kg (up to 90 kg) (less than the 
dose given in myocardial infarction or pulmonary embolism), 
administered in divided doses: 10% as a bolus over 1 minute, 
and the remaining 90% as a continuous infusion over the next 
60 minutes (Table 3). Alternatively, the use of intra-arterial 
thrombolysis, performed by interventionalists, aims at deliver-
ing the thrombolytic agent at higher concentrations directly 
into the thrombus.24,26 In selected cases, intra-arterial throm-
bolysis extends the window of intervention to 6 hours after the 
onset of AIS symptoms. Furthermore, combined therapy with 
intravenous thrombolysis and then intra-arterial thrombolysis 
is occasionally proposed, e.g. with low-dose intravenous (0.6 
mg/kg) rt-PA followed by 22 mg of intra-arterial rt-PA.27 Some 
investigators have examined the combined approach to lysis 
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with use of a platelet glycoprotein IIB/IIIA inhibitor and rt-PA 
and found it to be a safe approach.39 Finally, however, despite 
this apparent progress over the recent years in AIS manage-
ment, in the US, in 2009, the rate of thrombolytic therapy for 
AIS doubled (3.4% - 5.2%) compared to 2005,40 but remained 
well below desired rates. 
I N T E R v E N T I O N A L  T E C H N I q U E S
Endovascular interventional techniques for clot retraction 
in AIS patients have recently been introduced for those who 
are not candidates for rt-PA or who have failed intravenous 
therapy.4,41-49 Also, such devices have been used in combina-
tion with intravenous or intra-arterial therapy. For mechanical 
thrombectomy, two FDA-approved devices have become avail-
able,46,47 the Merci retriever (Concentric medical, Mountain 
View, CA, USA) and the Penumbra system (Penumbra, Inc., 
Alameda, CA, USA), with the former placed distally to the 
thrombus for clot retrieval and the latter proximally for clot 
disruption and aspiration. Initial results from trials employing 
these systems indicate that mechanical thrombectomy may 
be safe and effective for clot removal from large brain vessels 
after AIS.4 A recent review presented data on successful reca-
nalization with varying rates with these two approved devices 
(43% - 78% with the Merci retriever and 83% - 100% with 
the Penumbra system).41 Rates of harms were also variable, 
including symptomatic (0% - 10% with the former and 0% - 
11% with the latter device) or asymptomatic (28% - 43% and 
1% - 30%, respectively) intracranial hemorrhage and vessel 
perforation or dissection (0% - 7% and 0% - 5%, respectively). 
Older age, history of stroke, and higher baseline stroke severity 
scores were sorted out as predictors of harm, whereas success-
ful recanalization was a predictor of good outcome. However, 
in the accompanying editorial, great caution is advised in 
adopting neurothrombectomy over thrombolysis, before the 
completion of appropriately designed randomized studies 
establishing a clinical benefit from the use of such devices.42 
For cases of failure of arterial thrombolysis or mechanical 
thrombectomy or both, self-assisted revascularization with 
use of self-expanding stents have been used with promising 
results.50 However, in a very recent study, use of these stents 
in patients with transient ischemic attack or stroke attributed 
to stenosis 70-99% of a major intracranial artery failed to dem-
onstrate any benefit over aggressive medical management.51 
C O N C L U S I O N
There is currently a paradigm shift in the management of 
acute ischemic stroke (AIS) similar to that of acute myocardial 
infarction. Thrombolysis and endovascular interventional tech-
niques have been introduced and have ushered in a new era 
in more effective treatment strategies in these long-neglected 
patients. Data are compelling that treatment with intravenous 
TABLE 3. Thrombolysis in Acute Ischemic Stroke 
Regimen
● rt-PA/alteplase (Actilyse, Boehringer Ingelheim) 0.9 mg/kg (up 
to 90 kg), administered intravenously in divided doses with 10% 
as a bolus over 1 minute, and the remaining 90% as a continu-
ous infusion over the next 60 minutes*
Indications
● Acute ischemic stroke with definite neurologic deficit
● Onset of symptoms <3-4.5 hours**
● Age ≥18 years
● Patient/family consent (accepting a ~6% risk of intracerebral 
hemorrhage)
Contraindications
● Head injury / previous stroke within the last 3 months
● Hemorrhagic stroke / subarachnoid hemorrhage or history 
thereof 
● Markedly elevated BP (≥185/110 mm Hg) poorly controlled 
with medical therapy
● Puncture of noncompressible arterial site within the previous 7 
days
● Any active bleeding 
● known bleeding diathesis or platelet count ≤100,000/mm3, hep-
arin administered within 48 hours with overshooting aPTT, or 
receiving oral anticoagulant with INR >1.7
● Blood glucose concentration ≤50 mg/dl 
● Multilobar (large area) infarction on head CT (fear of hemor-
rhagic transformation)
Relative contraindications 
● Minor or rapidly improving stroke symptoms 
● Seizure at onset with postictal residual neurologic impairments
● Major surgery or severe trauma within the preceding 2 weeks
● GI or GU tract bleeding over last 3 weeks
● Acute myocardial infarction within the last 3 months
aPTT = activated partial thromboplastin time; BP = blood pressure; CT 
= computed tomography; GI = gastrointestinal; GU = genitorurinary; 
IV = intravenous; rt-PA = recombinant tissue-plasminogen activator
* No anticoagulants/antithrombotics for the first 24 hours; later 
permitted in absence of hemorrhage on CT scan. After IV rt-PA, a 
CT angiogram may be considered to examine for persistent arterial 
occlusion and guide intraarterial intervention with thrombolysis or 
mechanical thrombectomy or both.
** timing may be extended to ~8 hours for endovascular interventions 
(mechanical revascularization)4 
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rt-PA, in the time window of <3.0-4.5 hours after onset of AIS, 
is better than standard care and should be offered to appro-
priately selected patients.10-13,52 Significant progress has been 
achieved in this front, however penetration of these promising 
therapies into the medical community has been slow, albeit 
much slower than that noted during similar endeavors in shift-
ing gear in the management of acute myocardial infarction 
initially with thrombolysis and then with primary percutaneous 
coronary angioplasty. Advances in reperfusion techniques of 
AIS and in brain and vascular imaging will expand the number 
of patients who may benefit from such therapies. Until then, 
we have to work within a limited therapeutic window (≤ 3 
hours; or up to 6 hours in select patients), inform and educate 
the public about the warning signs for stroke, convince the 
authorities to establish and/or increase the number of stroke 
centers able to administer thrombolysis on a 24-hour basis 
or to provide advanced interventional perfusion techniques, 
and surpass our excessive fear of hemorrhagic complications. 
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